Xarelto vs Vascepa
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Xarelto | US Vascepa |
|---|---|---|
| Generic name | rivaroxaban Unverified catalogue summary (Generic name) for Xarelto in US; not checked against current local product information. | icosapent ethyl Unverified catalogue summary (Generic name) for Vascepa in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Xarelto in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Vascepa in US; not checked against current local product information. |
| Treats | Blood clots, nonvalvular atrial fibrillation Unverified catalogue summary (Treats) for Xarelto in US; not checked against current local product information. | High triglycerides, cardiovascular risk reduction Unverified catalogue summary (Treats) for Vascepa in US; not checked against current local product information. |
| Category | Cardiovascular Unverified catalogue summary (Category) for Xarelto in US; not checked against current local product information. | Cardiovascular Unverified catalogue summary (Category) for Vascepa in US; not checked against current local product information. |
| Manufacturer | Janssen Pharmaceuticals, Inc. Unverified catalogue summary (Manufacturer) for Xarelto in US; not checked against current local product information. | Amarin Pharma, Inc. (US distributor; manufactured for Amarin Pharmaceuticals Ireland Limited) Unverified catalogue summary (Manufacturer) for Vascepa in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Xarelto in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Vascepa in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Xarelto in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Vascepa in US; not checked against current local product information. |
| Est. TV ad spend | $210M | $90M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Xarelto in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Vascepa in US; not checked against current local product information. |
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Xarelto or Vascepa better?
This directory does not compare clinical effectiveness or safety. Listing Xarelto and Vascepa together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Xarelto and Vascepa?
The table shows catalogue identification and estimated advertising information for Xarelto and Vascepa, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Xarelto has the larger estimated TV advertising budget of the two.